ReviewJournal of inflammation research2026
Epigenetic Regulation of Pyroptosis in Kidney Disease: From Molecular Mechanisms to Therapeutic Potential.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney disease is a significant global health burden, driving substantial mortality and years of life lost. As a pro-inflammatory form of programmed cell death (PCD), pyroptosis is characterized by the rupture of the plasma membrane, cell lysis, and the release of intracellular contents. Emerging evidence has implicated pyroptosis as an important contributor to kidney disease pathogenesis, showing that it involves in structural damage and functional impairment in renal cells. Pyroptosis is regulated by genetically encoded intracellular mechanisms, with epigenetic modifications representing a prevalent and critical regulatory modality. Epigenetic regulation involves multiple regulatory layers, including DNA methylation, histone modifications, RNA modifications, and non-coding RNA-mediated regulation. This review explores how multiple epigenetic regulatory mechanisms collectively modulate pyroptosis and its crosstalk with other forms of PCD, highlighting their cell type-specific and context-dependent effects in kidney disease. Preclinical evidence indicates that these regulatory mechanisms modulate pyroptosis in renal tubular epithelial cells, podocytes, glomerular mesangial cells, macrophages, and renal cancer cells. This regulation may influence inflammatory responses, renal fibrosis, and tumor progression, potentially exerting renoprotective and antitumor effects. Building on this, we summarize emerging therapeutic strategies, including epigenetic-targeting drugs, Traditional Chinese Medicine interventions, and exosome-based therapies. These strategies aim to suppress excessive pyroptosis in non-malignant kidney diseases or induce tumor-cell pyroptosis in renal cancer. Future clinical trials are needed to validate these findings and facilitate their clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.